Irreversible Renal Damage after Transient Renin-Angiotensin System Stimulation: Involvement of an AT1-Receptor Mediated Immune Response

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Heijnen, Bart F J ^a   Nelissen, Jelly ^a   van Essen, Helma ^a   Fazzi, Gregorio E ^a   Cohen Tervaert, Jan W ^a   Peutz Kootstra, Carine J ^a   Mullins, John J ^b   Schalkwijk, Casper G ^a   Janssen, Ben J A ^a   Struijker Boudier, Harry A J ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; MOLECULAR MARKER; OSTEOPONTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; HYPERTENSION; IMMUNOHISTOCHEMISTRY; KIDNEY INJURY; MOLECULAR PATHOLOGY; NONHUMAN; PROTEIN EXPRESSION; RAT; RECEPTOR UPREGULATION; REGULATORY T LYMPHOCYTE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; T LYMPHOCYTE SUBPOPULATION; TH1 CELL;

ANIMALS; BIOLOGICAL MARKERS; HEMODYNAMICS; HYDRALAZINE; HYPERTENSION; KIDNEY; LOSARTAN; RATS; RATS, TRANSGENIC; RECEPTOR, ANGIOTENSIN, TYPE 1; RENIN-ANGIOTENSIN SYSTEM; T-LYMPHOCYTES; TIME FACTORS;

EID: 84874565363     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0057815     Document Type: Article

References (49)

1. Schiffrin EL, (2012) Vascular remodeling in hypertension: mechanisms and treatment. Hypertension 59: 367-374.
2. Ruiz-Ortega M, Ruperez M, Esteban V, Rodriguez-Vita J, Sanchez-Lopez E, et al. (2006) Angiotensin II: a key factor in the inflammatory and fibrotic response in kidney diseases. Nephrol Dial Transplant 21: 16-20.
3. Leibowitz A, Schiffrin EL, (2011) Immune mechanisms in hypertension. Curr Hypertens Rep 13: 465-472.
4. Harrison DG, Guzik TJ, Lob HE, Madhur MS, Marvar PJ, et al. (2011) Inflammation, immunity, and hypertension. Hypertension 57: 132-140.
5. Brown AJ, Casals-Stenzel J, Gofford S, Lever AF, Morton JJ, (1981) Comparison of fast and slow pressor effects of angiotensin II in the conscious rat. Am J Physiol 241: H381-388.
6. Griffin SA, Brown WC, MacPherson F, McGrath JC, Wilson VG, et al. (1991) Angiotensin II causes vascular hypertrophy in part by a non-pressor mechanism. Hypertension 17: 626-635.
7. Guzik TJ, Hoch NE, Brown KA, McCann LA, Rahman A, et al. (2007) Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction. J Exp Med 204: 2449-2460.
8. De Miguel C, Guo C, Lund H, Feng D, Mattson DL, (2011) Infiltrating T lymphocytes in the kidney increase oxidative stress and participate in the development of hypertension and renal disease. Am J Physiol Renal Physiol 300: F734-742.
9. Ozawa Y, Kobori H, Suzaki Y, Navar LG, (2007) Sustained renal interstitial macrophage infiltration following chronic angiotensin II infusions. Am J Physiol Renal Physiol 292: F330-339.
10. Crowley SD, Frey CW, Gould SK, Griffiths R, Ruiz P, et al. (2008) Stimulation of lymphocyte responses by angiotensin II promotes kidney injury in hypertension. Am J Physiol Renal Physiol 295: F515-524.
11. Shao J, Nangaku M, Miyata T, Inagi R, Yamada K, et al. (2003) Imbalance of T-cell subsets in angiotensin II-infused hypertensive rats with kidney injury. Hypertension 42: 31-38.
12. Barhoumi T, Kasal DA, Li MW, Shbat L, Laurant P, et al. (2011) T regulatory lymphocytes prevent angiotensin II-induced hypertension and vascular injury. Hypertension 57: 469-476.
13. Kasal DA, Barhoumi T, Li MW, Yamamoto N, Zdanovich E, et al. (2012) T regulatory lymphocytes prevent aldosterone-induced vascular injury. Hypertension 59: 324-330.
14. Nataraj C, Oliverio MI, Mannon RB, Mannon PJ, Audoly LP, et al. (1999) Angiotensin II regulates cellular immune responses through a calcineurin-dependent pathway. J Clin Invest 104: 1693-1701.
15. Zhang JD, Patel MB, Song YS, Griffiths R, Burchette J, et al. (2012) A novel role for type 1 Angiotensin receptors on T lymphocytes to limit target organ damage in hypertension. Circ Res 110: 1604-1617.
16. Wolak T, Kim H, Ren Y, Kim J, Vaziri ND, et al. (2009) Osteopontin modulates angiotensin II-induced inflammation, oxidative stress, and fibrosis of the kidney. Kidney Int 76: 32-43.
17. Nozaki Y, Nikolic-Paterson DJ, Snelgrove SL, Akiba H, Yagita H, et al. (2012) Endogenous Tim-1 (Kim-1) promotes T-cell responses and cell-mediated injury in experimental crescentic glomerulonephritis. Kidney Int 81: 844-855.
18. Lorenzen JM, Neunhoffer H, David S, Kielstein JT, Haller H, et al. (2010) Angiotensin II receptor blocker and statins lower elevated levels of osteopontin in essential hypertension-results from the EUTOPIA trial. Atherosclerosis 209: 184-188.
19. Heijnen BFJ, Peutz-Kootstra CJ, Mullins JJ, Janssen BJA, Struijker-Boudier HAJ, (2011) Transient Renin-Angiotensin System Stimulation in an Early Stage of Life Causes Sustained Hypertension in Rats. J Hypertens 29: 2369-2380.
20. Kantachuvesiri S, Fleming S, Peters J, Peters B, Brooker G, et al. (2001) Controlled hypertension, a transgenic toggle switch reveals differential mechanisms underlying vascular disease. J Biol Chem 276: 36727-36733.
21. Mitchell KD, Bagatell SJ, Miller CS, Mouton CR, Seth DM, et al. (2006) Genetic clamping of renin gene expression induces hypertension and elevation of intrarenal Ang II levels of graded severity in Cyp1a1-Ren2 transgenic rats. J Renin Angiotensin Aldosterone Syst 7: 74-86.
22. Peters B, Grisk O, Becher B, Wanka H, Kuttler B, et al. (2008) Dose-dependent titration of prorenin and blood pressure in Cyp1a1ren-2 transgenic rats: absence of prorenin-induced glomerulosclerosis. J Hypertens 26: 102-109.
23. Baumann M, Janssen BJ, Hermans JJ, Peutz-Kootstra C, Witzke O, et al. (2007) Transient AT1 receptor-inhibition in prehypertensive spontaneously hypertensive rats results in maintained cardiac protection until advanced age. J Hypertens 25: 207-215.
24. Devarajan P, (2010) The use of targeted biomarkers for chronic kidney disease. Adv Chronic Kidney Dis 17: 469-479.
25. Howard CG, Mullins JJ, Mitchell KD, (2010) Transient induction of ANG II-dependent malignant hypertension causes sustained elevation of blood pressure and augmentation of the pressor response to ANG II in CYP1A1-REN2 transgenic rats. Am J Med Sci 339: 543-548.
26. Mori K, Nakao K, (2007) Neutrophil gelatinase-associated lipocalin as the real-time indicator of active kidney damage. Kidney Int 71: 967-970.
27. Umetsu SE, Lee WL, McIntire JJ, Downey L, Sanjanwala B, et al. (2005) TIM-1 induces T cell activation and inhibits the development of peripheral tolerance. Nat Immunol 6: 447-454.
28. Denhardt DT, Noda M, O'Regan AW, Pavlin D, Berman JS, (2001) Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival. J Clin Invest 107: 1055-1061.
29. Honetschlagerova Z, Sporkova A, Kopkan L, Huskova Z, Hwang SH, et al. (2011) Inhibition of soluble epoxide hydrolase improves the impaired pressure-natriuresis relationship and attenuates the development of hypertension and hypertension-associated end-organ damage in Cyp1a1-Ren-2 transgenic rats. J Hypertens 29: 1590-1601.
30. Knier B, Cordasic N, Klanke B, Heusinger-Ribeiro J, Daniel C, et al. (2011) Effect of the plasminogen-plasmin system on hypertensive renal and cardiac damage. J Hypertens 29: 1602-1612.
31. Eddy AA, Fogo AB, (2006) Plasminogen activator inhibitor-1 in chronic kidney disease: evidence and mechanisms of action. J Am Soc Nephrol 17: 2999-3012.
32. Graciano ML, Mouton CR, Patterson ME, Seth DM, Mullins JJ, et al. (2007) Renal vascular and tubulointerstitial inflammation and proliferation in Cyp1a1-Ren2 transgenic rats with inducible ANG II-dependent malignant hypertension. Am J Physiol Renal Physiol 292: F1858-1866.
33. Kato T, Mizuno S, Kamimoto M, (2010) The decreases of nephrin and nuclear WT1 in podocytes may cause albuminuria during the experimental sepsis in mice. Biomed Res 31: 363-369.
34. Huskova Z, Vanourkova Z, Erbanova M, Thumova M, Opocensky M, et al. (2010) Inappropriately high circulating and intrarenal angiotensin II levels during dietary salt loading exacerbate hypertension in Cyp1a1-Ren-2 transgenic rats. J Hypertens 28: 495-509.
35. Vanourkova Z, Kramer HJ, Huskova Z, Vaneckova I, Opocensky M, et al. (2006) AT1 receptor blockade is superior to conventional triple therapy in protecting against end-organ damage in Cyp1a1-Ren-2 transgenic rats with inducible hypertension. J Hypertens 24: 2465-2472.
36. Mitchell KD, Mullins JJ, (2005) Enhanced tubuloglomerular feedback in Cyp1a1-Ren2 transgenic rats with inducible ANG II-dependent malignant hypertension. Am J Physiol Renal Physiol 289: F1210-1216.
37. Williams DE, Prieto MC, Mullins JJ, Navar LG, Mitchell KD, (2010) AT1 receptor blockade prevents the increase in blood pressure and the augmentation of intrarenal ANG II levels in hypertensive Cyp1a1-Ren2 transgenic rats fed with a high-salt diet. Am J Med Sci 339: 356-361.
38. Takeichi N, Hamada J, Takimoto M, Fujiwara K, Kobayashi H, (1988) Depression of T cell-mediated immunity and enhancement of autoantibody production by natural infection with microorganisms in spontaneously hypertensive rats (SHR). Microbiol Immunol 32: 1235-1244.
39. Cohen Tervaert JW, (2011) Hypertension: an autoimmune disease? Hypertens Res 34: 443-444.
40. Murphy TJ, Ni Choileain N, Zang Y, Mannick JA, Lederer JA, (2005) CD4+CD25+ regulatory T cells control innate immune reactivity after injury. J Immunol 174: 2957-2963.
41. Kvakan H, Kleinewietfeld M, Qadri F, Park JK, Fischer R, et al. (2009) Regulatory T cells ameliorate angiotensin II-induced cardiac damage. Circulation 119: 2904-2912.
42. Tamosiuniene R, Tian W, Dhillon G, Wang L, Sung YK, et al. (2011) Regulatory T cells limit vascular endothelial injury and prevent pulmonary hypertension. Circ Res 109: 867-879.
43. Schiffrin EL, (2010) T lymphocytes: a role in hypertension? Curr Opin Nephrol Hypertens 19: 181-186.
44. Madhur MS, Lob HE, McCann LA, Iwakura Y, Blinder Y, et al. (2010) Interleukin 17 promotes angiotensin II-induced hypertension and vascular dysfunction. Hypertension 55: 500-507.
45. Bromley SK, Mempel TR, Luster AD, (2008) Orchestrating the orchestrators: chemokines in control of T cell traffic. Nat Immunol 9: 970-980.
46. Viel EC, Lemarie CA, Benkirane K, Paradis P, Schiffrin EL, (2010) Immune regulation and vascular inflammation in genetic hypertension. Am J Physiol Heart Circ Physiol 298: H938-944.
47. Fu S, Zhang N, Yopp AC, Chen D, Mao M, et al. (2004) TGF-beta induces Foxp3+ T-regulatory cells from CD4+ CD25- precursors. Am J Transplant 4: 1614-1627.
48. Marvar PJ, Thabet SR, Guzik TJ, Lob HE, McCann LA, et al. (2010) Central and peripheral mechanisms of T-lymphocyte activation and vascular inflammation produced by angiotensin II-induced hypertension. Circ Res 107: 263-270.
49. Lever AF (1993) Slow developing pressor effect of angiotensin II and vascular structure. J Hypertens Suppl 11: S27-28.